Stock listing
NASDAQ:INDP Indaptus Therapeutics, Inc. Stock
Home listing (NASDAQ) of Indaptus Therapeutics, Inc.
Follow Indaptus Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:INDP
$2.82 USD -0.47 (-14.3%)
Close on Nov 20, 2026
- Day range
- $2.78 – $3.16 USDNov 20, 2026
- Volume
- 239,362 sharesNov 20, 2026
- Market cap
- $433.2M USDAt the close on Nov 20, 2026 · price × 153.6M shares outstanding
- 52-week range
- $0.92 – $5.96 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.10M USDMedian day 363,581 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:INDP · Home | $2.82 USD | -0.47 (-14.3%) | 239,362 | $3.11 | $3.16 | $2.78 | $3.29 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INDP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.82 | -0.47 | -14.3% | $3.11 | $3.16 | $2.78 | 239,362 | |
| $3.29 | -0.03 | -0.9% | $3.28 | $3.44 | $3.17 | 166,779 | |
| $3.32 | -0.13 | -3.8% | $3.42 | $3.595 | $3.125 | 278,348 | |
| $3.45 | +0.28 | +8.8% | $3.17 | $3.55 | $3.095 | 363,581 | |
| $3.17 | +0.02 | +0.6% | $3.06 | $3.29 | $3.05 | 113,195 | |
| $3.15 | -0.06 | -1.9% | $3.15 | $3.20 | $3.05 | 118,325 | |
| $3.21 | +0.31 | +10.7% | $3.05 | $3.29 | $3.03 | 264,680 | |
| $2.90 | -0.23 | -7.3% | $3.15 | $3.19 | $2.66 | 475,018 | |
| $3.13 | -0.19 | -5.7% | $3.25 | $3.44 | $3.10 | 189,797 | |
| $3.32 | +0.16 | +5.1% | $3.20 | $3.54 | $3.20 | 274,438 | |
| $3.16 | -0.14 | -4.2% | $3.30 | $3.39 | $2.985 | 204,560 | |
| $3.30 | +0.06 | +1.9% | $3.25 | $3.35 | $3.105 | 111,353 | |
| $3.24 | -0.26 | -7.4% | $3.31 | $3.40 | $3.21 | 111,967 | |
| $3.50 | +0.41 | +13.3% | $3.05 | $3.52 | $3.05 | 226,078 | |
| $3.09 | -0.25 | -7.5% | $3.34 | $3.40 | $3.00 | 241,849 | |
| $3.34 | +0.01 | +0.3% | $3.37 | $3.438 | $3.30 | 82,628 | |
| $3.33 | +0.025 | +0.8% | $3.30 | $3.45 | $3.223 | 213,464 | |
| $3.305 | -0.035 | -1.0% | $3.38 | $3.52 | $3.26 | 366,029 | |
| $3.34 | +0.18 | +5.7% | $3.22 | $3.42 | $3.16 | 352,838 | |
| $3.16 | +0.17 | +5.7% | $3.00 | $3.22 | $2.865 | 287,477 | |
| $2.99 | -0.17 | -5.4% | $3.23 | $3.23 | $2.93 | 223,700 | |
| $3.16 | +0.20 | +6.8% | $2.93 | $3.28 | $2.845 | 528,900 | |
| $2.96 | +0.23 | +8.4% | $2.75 | $2.97 | $2.70 | 218,400 | |
| $2.73 | +0.10 | +3.8% | $2.55 | $2.796 | $2.47 | 178,200 | |
| $2.63 | -0.22 | -7.7% | $2.88 | $2.92 | $2.55 | 496,200 | |
| $2.85 | +0.64 | +29.0% | $2.25 | $2.89 | $2.25 | 1,324,100 | |
| $2.21 | -0.18 | -7.5% | $2.34 | $2.40 | $2.025 | 449,800 | |
| $2.39 | -0.05 | -2.0% | $2.44 | $2.52 | $2.35 | 120,000 | |
| $2.44 | -0.07 | -2.8% | $2.50 | $2.714 | $2.40 | 363,300 | |
| $2.51 | +0.14 | +5.9% | $2.35 | $2.635 | $2.35 | 467,600 | |
| $2.37 | +0.11 | +4.9% | $2.37 | $2.53 | $2.29 | 506,900 | |
| $2.26 | -0.33 | -12.7% | $2.57 | $2.57 | $2.225 | 589,200 | |
| $2.59 | +0.08 | +3.2% | $2.51 | $2.61 | $2.39 | 279,200 | |
| $2.51 | +0.13 | +5.5% | $2.35 | $2.53 | $2.25 | 361,500 | |
| $2.38 | +0.26 | +12.3% | $2.11 | $2.416 | $1.94 | 568,100 | |
| $2.12 | -0.18 | -7.8% | $2.28 | $2.408 | $2.082 | 478,500 | |
| $2.30 | -0.55 | -19.3% | $2.87 | $2.91 | $2.26 | 643,000 | |
| $2.85 | -0.44 | -13.4% | $3.24 | $3.315 | $2.81 | 589,300 | |
| $3.29 | -0.56 | -14.5% | $3.78 | $3.834 | $3.125 | 584,200 | |
| $3.85 | -0.15 | -3.7% | $3.995 | $3.995 | $3.46 | 570,900 | |
| $4.00 | +0.23 | +6.1% | $3.77 | $4.11 | $3.76 | 513,300 | |
| $3.77 | -0.22 | -5.5% | $3.93 | $4.22 | $3.566 | 624,600 | |
| $3.99 | +0.90 | +29.1% | $3.10 | $4.06 | $2.95 | 1,270,100 | |
| $3.09 | -0.46 | -13.0% | $3.55 | $3.55 | $2.90 | 718,800 | |
| $3.55 | -0.38 | -9.7% | $3.85 | $4.09 | $3.51 | 1,163,500 | |
| $3.93 | +0.72 | +22.4% | $3.30 | $3.98 | $3.27 | 915,800 | |
| $3.21 | -0.43 | -11.8% | $3.66 | $3.69 | $2.90 | 1,200,600 | |
| $3.64 | +0.50 | +15.9% | $3.40 | $3.695 | $3.05 | 1,960,500 | |
| $3.14 | +0.37 | +13.4% | $2.80 | $3.18 | $2.69 | 1,378,500 | |
| $2.77 | +0.21 | +8.2% | $2.70 | $2.94 | $2.46 | 1,797,900 | |
| $2.56 | +0.48 | +23.1% | $2.00 | $2.63 | $1.97 | 3,181,100 | |
| $2.08 | +0.23 | +12.4% | $1.92 | $2.39 | $1.89 | 5,675,600 | |
| $1.85 | +0.63 | +51.6% | $1.285 | $1.94 | $1.27 | 8,463,100 | |
| $1.22 | +0.06 | +5.2% | $1.20 | $1.235 | $1.17 | 133,100 | |
| $1.16 | -0.01 | -0.9% | $1.16 | $1.19 | $1.14 | 249,900 | |
| $1.17 | +0.04 | +3.5% | $1.17 | $1.20 | $1.131 | 331,800 | |
| $1.13 | -0.015 | -1.3% | $1.10 | $1.162 | $1.10 | 73,100 | |
| $1.145 | +0.005 | +0.4% | $1.14 | $1.17 | $1.09 | 140,300 | |
| $1.14 | -0.02 | -1.7% | $1.16 | $1.185 | $1.10 | 104,000 | |
| $1.16 | +0.02 | +1.8% | $1.13 | $1.24 | $1.09 | 404,600 | |
| $1.14 | +0.045 | +4.1% | $1.09 | $1.16 | $1.06 | 206,000 | |
| $1.095 | -0.065 | -5.6% | $1.15 | $1.18 | $1.09 | 496,900 | |
| $1.16 | -0.13 | -10.1% | $1.24 | $1.29 | $1.13 | 292,700 | |
| $1.29 | -0.09 | -6.5% | $1.39 | $1.58 | $1.18 | 1,134,400 | |
| $1.38 | +0.44 | +46.8% | $0.942 | $1.42 | $0.94 | 11,750,400 |
Splits
3 splits since 2020 · NASDAQ:INDP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-28 | Consolidation | |
| 1-for-4 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:INDP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest news
Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 13, 2026
Closed $3.45 (+8.8%) on Nov 16, 2026
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 13, 2026
Closed $1.06 (+3.9%) on Aug 13, 2026
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 15, 2026
Closed $1.59 (-9.1%) on May 15, 2026
Indaptus Therapeutics Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Dec 30, 2025
Closed $2.72 (0.0%) on Dec 30, 2025
Indaptus Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in the last 12 months · 63 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 6 decks · latest September 2024
Where Indaptus Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:INDP · Home listing · This page | NASDAQ | United States | USD |
| BOATS:INDP | BOATS | United States | USD |
Valuation
Price/book 41.9× against a median of 3.5×: the highest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $402.6M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 41.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.77
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. · NASDAQ:INDP | US$433.2M | US$402.6M | n/a | n/a | n/a | 41.9× | n/a | 0.0× | 1.77 |
| CytomX Therapeutics, Inc. · NASDAQ:CTMX | US$442.5M | US$98.96M | n/a | 7.0× | n/a | 1.6× | −609.0% | 0.0× | 1.21 |
| Capricor Therapeutics, Inc. · NASDAQ:CAPR | US$441.3M | US$335.9M | n/a | n/a | n/a | 2.1× | n/a | 0.4× | 0.94 |
| Hansa Biopharma AB · OMXSTO:HNSA | US$440.3M | US$487.4M | n/a | 26.3× | n/a | n/a | −406.5% | n/a | n/a |
| Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373 | US$438.4M | US$407.2M | n/a | 16.2× | n/a | 19.4× | −57.0% | 0.9× | n/a |
| Clarity Pharmaceuticals Ltd. · ASX:CU6 | US$437.1M | US$239.0M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | n/a |
| Hyundai Bioscience Co. Ltd. · KRX:048410 | US$435.2M | US$408.7M | n/a | 166× | n/a | 5.7× | −861.5% | 0.1× | n/a |
| Oculis Holding AG · NASDAQ:OCS | US$434.8M | US$184.3M | n/a | 22,112× | n/a | 1.8× | n/a | 0.0× | 0.99 |
| Rznomics Inc. · KRX:476830 | US$432.5M | US$406.0M | n/a | n/a | n/a | 12.5× | n/a | 0.0× | n/a |
| LongBio Pharma (Suzhou) Co., Ltd. Class H · HKEX:1779 | US$430.7M | US$402.1M | n/a | n/a | n/a | 20.5× | n/a | 0.0× | n/a |
| Ovid Therapeutics Inc. · NASDAQ:OVID | US$429.7M | US$305.4M | n/a | 210× | n/a | 2.2× | n/a | 0.1× | 1.37 |
| Median of the others | US$436.1M | US$369.0M | 96.0× | 3.5× | −507.7% | 0.0× | 1.10 |
Forecasts
Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.43 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Indaptus' Co-Chief | Executive Officer and Chairman of the Board |
Board
| Director | Role |
|---|---|
| Indaptus' Co-Chief | Executive Officer and Chairman of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | +9.5% |
| Q2 2026 | Aug 13, 2026 | +4.9% |
| Q4 2025 | Mar 17, 2026 · After close | −4.6% |
| Q3 2025 | Nov 12, 2025 · Before open | +6.3% |
| Q2 2025 | Aug 13, 2025 · Before open | +2.4% |
| Q1 2025 | May 14, 2025 · Before open | −3.7% |
| Q4 2024 | Mar 13, 2025 | −4.2% |
| Q3 2024 | Nov 12, 2024 · Before open | −5.0% |
| Q2 2024 | Aug 12, 2024 · Before open | +0.6% |
| Q1 2024 | May 8, 2024 · Before open | +1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 13, 2024 · Before open | −3.4% |
| Q3 2023 | Nov 6, 2023 · After close | −10.1% |
| Q2 2023 | Aug 14, 2023 · Before open | +7.8% |
| Q1 2023 | May 11, 2023 · Before open | −9.3% |
| Q4 2022 | Mar 17, 2023 · Before open | +6.3% |
| Q3 2022 | Nov 10, 2022 · After close | +16.2% |
| Q2 2022 | Aug 8, 2022 · Before open | −0.6% |
| Q1 2022 | May 12, 2022 · Before open | +5.0% |
| Q4 2021 | Mar 21, 2022 · Before open | −0.8% |
| Q3 2021 | Nov 15, 2021 · Before open | −9.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2024) | Investor deck | 30 slides | September 2024 |
| Investor Presentation (April 2024) | Investor deck | 28 slides | April 2024 |
| Investor Presentation (January 2024) | Investor deck | 25 slides | January 2024 |
| Investor Presentation (October 2022) | Investor deck | 26 slides | October 2022 |
| Investor Presentation (November 2021) | Investor deck | 42 slides | Nov 15, 2021 |
| Investor Presentation (August 2021) | Investor deck | 40 slides | Aug 3, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of non-voting convertible preferred stock Closed: US$6M raised Buyers: David E. Lazar ($6.0 million investment for 300,000 Series AA and 700,000 Series AAA preferred shares; appointed Co-CEO and Chairman) | Dec 30, 2025 |
| Private placement of convertible promissory notes and accompanying warrants Tranche closed: US$5.7M raised · Warrants to purchase 200% of the conversion shares, issued following conversion of the… · Paulson Investment Company, LLC Dealers: Paulson Investment Company, LLC (lead) Use of proceeds: Research and development including funding a Phase 1b/2 clinical trial, working capital and general corporate purposes | Jul 1, 2025 |
| Private placement of shares of common stock and accompanying warrants Announced: about US$2.25M · US$1.065 a share · Warrants at US$0.94 for 60 months · Paulson Investment Company, LLC Dealers: Paulson Investment Company, LLC (lead) Use of proceeds: Research and development activities, working capital and general corporate purposes | Jan 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Cost of revenue | 735 | 1.28K | 1.78K | 1.40K | 852 | 854.0K | 859.0K | 829.0K | 701.0K | |
| Gross profit | -735 | -1.28K | -1.78K | -1.40K | -852 | -854.0K | -859.0K | -829.0K | -701.0K | |
| Research and development | 9.34M | 7.25M | 7.62M | 6.32M | 2.52M | 2.66M | 26.7M | 35.4M | 24.3M | 10.1M |
| Selling, general and administrative | 10.5M | 8.11M | 8.76M | 8.59M | 5.21M | 944.2K | 542.6K | |||
| Operating income | -19.8M | -15.4M | -16.4M | -14.9M | -7.73M | -3.60M | -34.9M | -43.3M | -29.4M | -13.8M |
| Depreciation and amortization | 0 | 735 | 1.28K | 1.78K | 1.40K | 852 | 854.0K | 859.0K | 829.0K | 701.0K |
| EBITDA | -19.8M | -15.4M | -16.4M | -14.9M | -7.73M | -3.60M | -34.1M | -42.5M | -28.6M | -13.1M |
| Interest expense | 588.1K | 17.7K | 15.1K | 15.0K | 23.0K | 17.0K | 16.0K | |||
| Income before tax | -20.8M | -15.0M | -15.4M | -14.3M | -7.71M | -3.58M | -47.0M | -43.4M | -28.9M | -13.4M |
| Income tax | 1.72K | 1.70K | 2.45K | 30 | 1.65K | 800 | 638.0K | 103.0K | 29.0K | |
| Net income | -20.8M | -15.0M | -15.4M | -14.3M | -7.71M | -3.58M | -47.6M | -43.5M | -28.9M | -13.4M |
| Earnings per share, basic | -21.58 | -44.96 | -1.83 | -1.73 | -1.89 | -1.84 | -3,156.85 | -3,126.97 | -3,667.26 | -2,614.87 |
| Earnings per share, diluted | -21.58 | -44.96 | -1.83 | -1.73 | -1.89 | -1.84 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.51M | 5.79M | 13.4M | 9.63M | 39.1M | 1.64M | 9.29M | 39.2M | 53.4M | 16.4M |
| Short-term investments | 0 | 16.8M | 0 | 770.0K | 1.33M | 1.82M | 1.85M | |||
| Receivables | 21.1K | 3.49M | 2.03M | 478.0K | 721.0K | |||||
| Current assets | 9.31M | 6.62M | 14.0M | 27.2M | 40.4M | 1.73M | 13.7M | 43.6M | 56.3M | 20.7M |
| Property, plant and equipment | 735 | 2.02K | 3.80K | 1.35K | 2.20K | |||||
| Total assets | 9.31M | 7.34M | 14.9M | 28.1M | 40.6M | 1.78M | 21.3M | 61.5M | 64.5M | 24.7M |
| Accounts payable | 544.1K | 870.2K | 806.0K | 1.38M | 2.54M | 156.0K | 3.51M | 2.85M | 1.85M | 1.15M |
| Current liabilities | 6.16M | 3.39M | 2.77M | 3.43M | 4.60M | 2.02M | 8.34M | 7.66M | 5.75M | 1.92M |
| Total debt | 84.2K | 175.1K | 80.5K | 169.3K | 169.3K | 1.34M | ||||
| Total liabilities | 6.16M | 3.39M | 2.85M | 3.43M | 4.68M | 2.02M | 9.74M | 7.96M | 5.75M | 2.02M |
| Shareholders' equity | 3.15M | 3.94M | 12.1M | 24.6M | 35.9M | -237.7K | 11.5M | 53.5M | 58.8M | 22.7M |
| Shares outstanding | 2.17M | 428.8K | 8.40M | 8.40M | 8.26M | 1.94M | 15.1K | 13.9K | 7.88K | 5.11K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14.8M | -12.3M | -13.4M | -13.1M | -11.3M | -3.32M | -29.0M | -39.1M | -22.1M | -12.0M |
| Capital spending | -4 | 0 | -5 | -172.6K | -3.85K | -8.21M | -921.0K | -9.60M | -5.00M | -482.0K |
| Free cash flow | -14.8M | -12.3M | -13.4M | -13.3M | -11.3M | -3.32M | -30.0M | -48.7M | -27.1M | -12.5M |
| Cash from investing | 17.1M | -16.4M | 447.7K | 447.7K | -3.21M | -9.30M | -4.75M | 4.72M | ||
| Cash from financing | 17.5M | 4.75M | 0 | 363.1K | 48.3M | 1.16M | 2.37M | 35.1M | 63.7M | |
| Change in cash | 2.72M | -7.58M | 3.74M | -29.5M | 37.5M | -2.16M | -30.0M | -14.1M | 37.0M | -7.28M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Oct 5, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 30, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 9, 2026 | Material contract | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K/A · Current report, amended | Sep 4, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 4, 2026 | Management or board change | SEC |
| 424B5 · Prospectus | Sep 4, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 1, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 26, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 26, 2026 | Other filings | SEC |
| S-3 · Registration statement | Aug 17, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Jul 20, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Jul 16, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 26, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Jun 26, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Jun 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 5, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 29, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Apr 24, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 22, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Apr 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 3, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Apr 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 24, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 27, 2026 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Feb 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Feb 12, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jan 21, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 20, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Jan 8, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 2, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| S-1/A · Registration statement, amended | Sep 3, 2025 | Offer document | SEC |
| S-1 · Registration statement | Sep 2, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 2, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 18, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 13, 2025 | Offer document | SEC |
| S-3 · Registration statement | Aug 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 29, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jul 16, 2025 | Current report | SEC |
| 8-K · Current report | Jul 1, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Jun 23, 2025 | Meeting notice | SEC |
| D | Jun 20, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Jun 13, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 13, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| DRS · Draft registration statement | Mar 27, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 14, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| POS AM · Amendment to an effective registration | Mar 13, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 12, 2025 | Other filings | SEC |
| S-1 · Registration statement | Feb 12, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 12, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Feb 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 7, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 5, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 31, 2025 | Current report | SEC |
| D | Jan 22, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 14, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jan 2, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 30, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 23, 2024 | Offer document | SEC |
| D | Dec 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 22, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 22, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Oct 22, 2024 | Current report | SEC |
| SC 13D · Big-stake notice | Oct 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| D/A | Oct 4, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 17, 2024 | Other filings | SEC |
| S-1 · Registration statement | Sep 12, 2024 | Offer document | SEC |
| D | Aug 22, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Aug 7, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Aug 6, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Management or board change | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 25, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 13, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2024 | Results | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 23, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2023 | Results | SEC |
| 8-K · Current report | Nov 6, 2023 | Current report | SEC |
| 8-K · Current report | Oct 31, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 16, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 16, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 8-K · Current report | Aug 10, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
This page holds 200 of 345 filings. Open Filings
Cap table
Built by 6ix from Indaptus Therapeutics, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 153,602,583
- Fully diluted
- 153,602,583
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 153,602,583 | Nov 13, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · expire about Jun 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 153,602,583 |
| Sep 30, 2026 | 133,242,324 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Natan Other companies: Aterian, Inc. (Director · Since at least Jul 17, 2026); Quantum Cyber N.V. (Board Member · Since at least Apr 22, 2026); Sow Good Inc. (Director · Since at least Dec 31, 2025); FiEE, Inc (Director · Since at least Nov 8, 2023); Sunshine Biopharma Inc. (director · Since at least Feb 10, 2022); The Crypto Company (Chief Financial Officer · Mar 12, 2025 – Mar 12, 2025 · Past); Bio Green Med Solution, Inc. (Director · Jan 2, 2025 – Feb 26, 2025 · Past); CapForce Inc. (Director · Mar 25, 2024 – Apr 11, 2024 · Past); Vivakor, Inc. (Director · Dec 15, 2022 – Dec 15, 2022 · Past); Titan Pharmaceuticals Inc (Director · Aug 15, 2022 – Oct 25, 2023 · Past); NetBrands Corp. (Director · Feb 24, 2021 – Apr 25, 2022 · Past); PharmaNet Development Group Inc (Former EVP · Aug 3, 2007 – Dec 10, 2007 · Past) | Director · Since at least Jan 7, 2026 |
| David Lazar Other companies: Aterian, Inc. (Chair of the Board · Since at least Apr 27, 2026); Quantum Cyber N.V. (CEO · Since at least Feb 13, 2026); Sow Good Inc. (Chief Executive Officer and Chair of the Board · Since at least Dec 31, 2025); Kala Bio, Inc. (Chief Executive Officer, Director · Since at least Nov 23, 2025); Stablecoin Development Corporation (Chief Executive Officer, Director · Since at least Aug 19, 2025); Bio Green Med Solution, Inc. (Interim CEO · Jan 2, 2025 – Feb 26, 2025 · Past); LQR House Inc. (President, Director · Oct 15, 2024 – Apr 2, 2025 · Past); CapForce Inc. (Chief Executive Officer, Director · Mar 25, 2024 – Jul 30, 2024 · Past); FiEE, Inc (Director · Dec 29, 2023 – Feb 18, 2025 · Past); Titan Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 24, 2023 – Jul 26, 2023 · Past) | Director · Since at least Dec 22, 2025 |
| William B Hayes Other companies: Builders FirstSource, Inc. (Director · Since at least Oct 14, 2019); Intec Pharma Ltd (Director · Jan 1, 2019 – Jul 15, 2020 · Past); Patheon N.V. (Director · Jul 20, 2016 – Aug 29, 2017 · Past); Labcorp Holdings Inc. (Chief Financial Officer, EVP · Feb 9, 2012 – Jun 6, 2014 · Past); Orchid Cellmark Inc (EVP and Treasurer, Director · Dec 9, 2011 – Dec 9, 2011 · Past) | Director · Since at least Jul 23, 2021 |
| Avraham Ben-Tzvi Other companies: Aterian, Inc. (Director · Since at least Jul 17, 2026); Quantum Cyber N.V. (Director · Since at least Apr 22, 2026); Black Titan Corp (Director · Since at least Oct 1, 2025); Titan Pharmaceuticals Inc (Director · Since at least Oct 1, 2025) | Director · Since at least Dec 22, 2025 |
| Matthew Charles McMurdo Other companies: CapForce Inc. (Director · Mar 25, 2024 – Apr 11, 2024 · Past); FiEE, Inc (Director · Dec 29, 2023 – Sep 26, 2024 · Past); Titan Pharmaceuticals Inc (Director · Aug 15, 2022 – Oct 25, 2023 · Past) | Director · Since at least Feb 26, 2026 |
| Hila Karah Other companies: DarioHealth Corp. (Board Member · Since at least Mar 3, 2016); Intec Pharma Ltd (Director · Jan 1, 2019 – Jul 15, 2020 · Past) | Director · Since at least Jul 23, 2021 |
| Roger Pomerantz Other companies: Enlivex Ltd. (Director · Since at least Mar 18, 2026); Viracta Therapeutics Inc (Director · May 25, 2022 – Nov 25, 2024 · Past) | Director · Since at least Sep 30, 2022 |
| Walt Addison Linscott Other companies: Intec Pharma Ltd (Chief Business Officer · Jan 1, 2019 – Sep 16, 2020 · Past); Cocrystal Pharma, Inc. (GENERAL COUNSEL AND SECRETARY · Jul 21, 2015 – Jul 21, 2015 · Past) | Chief Operating Officer · Since at least Jul 23, 2021 |
| Jeffrey A. Meckler Other companies: Travere Therapeutics, Inc. (Director · Since at least May 14, 2021) | Co-Chief Executive Officer, Director · Since at least Jul 23, 2021 |
| Jerome D. Jabbour Other companies: Matinas BioPharma Holdings, Inc. (Co-founder, Chairman & Chief Executive Officer · Since at least Mar 22, 2018) | Director · Since at least Feb 26, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Junyi Dai Other companies: Mega Matrix Inc. (Director · May 10, 2024 – May 10, 2024 · Past) | Chief Executive Officer · Since at least Mar 23, 2026 |
| Nir Sassi Other companies: Intec Pharma Ltd (Chief Financial Officer · Jan 1, 2019 – Sep 16, 2020 · Past) | Chief Financial Officer · Since at least Jul 23, 2021 |
| Robert Martell Other companies: Curis, Inc. (Head of Research & Development · Sep 14, 2011 – Jan 20, 2023 · Past) | Director · Since at least Feb 13, 2023 |
| Boyan Vesselinov Litchev | Chief Medical Officer · Jan 31, 2022 – Feb 1, 2022 · Past |
| Indaptus' Co-Chief | Executive Officer and Chairman of the Board · Since at least Dec 30, 2025 |
| Mark John Gilbert | Director · Since at least Jun 10, 2025 |
| Michael James Newman | CSO and Director, Director · Since at least Dec 22, 2025 |
| Qinglai Lu | Director · Since at least Apr 8, 2026 |
Log in to ask 6ix AI your own questions about Indaptus Therapeutics, Inc.